热门资讯> 正文

早些时候报道，Travere Thereutics获得FDA批准FILSPARI治疗不伴肾病综合征的局灶节段性球体硬化症，蛋白尿减少48%，而在3期DUPFLEX研究中厄贝沙坦减少27%

2026-04-14 14:19

FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome
Additional indication for FILSPARI expands total addressable population to more than 100,000 patients in the U.S, including more than 30,000 patients with FSGS
Label aligns with KDIGO clinical practice guidelines for managing patients with FSGS

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。